Objective To assess the prevalence of overweight/obesity in a cohort of Italian children with Down syndrome (DS) and to investigate the correlation of both obesity and DS with nonalcoholic fatty liver disease (NAFLD).
D
own syndrome (DS) is the most common chromosomal disorder, with a prevalence ranging from 6.1 to 13.1 per 10 000 people. 1 Although improvements in medical care have led to an increased life expectancy, efforts are still needed to implement healthcare services for individuals affected by this condition. 2 Children with DS exhibit a high prevalence of various comorbid medical conditions. 3 Among the many conditions associated with DS in the pediatric setting, obesity is one of the most common. Childhood obesity is following the widespread epidemic of adult obesity. 4 In fact, it is estimated that at least 155 million children worldwide are overweight or obese. 5, 6 The prevalence of overweight and obesity in children with DS is greater than general pediatric population, ranging from 23% to 70%. 7 Aburawi et al 8 demonstrated that rates of overweight and obesity increase after 2 years of age in children with DS.
Risk factors of overweight/obesity in the general pediatric population include increased unfavorable dietary patterns, lower levels of physical activity, and comorbidities such as thyroid disorders and severe congenital heart diseases. 9 The same factors also could influence body weight in children with DS. [10] [11] [12] The few available studies on these subjects do not yet provide convincing evidence for any specific relationship. In addition, several studies reported that high levels of leptin, a well-known adipocytokine, could be an additional determinant of obesity in children with DS. [13] [14] [15] Similarly to children without DS, obesity in children with DS is associated with several diseases including obstructive sleep apnea, 16 orthopedic and gait abnormalities, 17 and metabolic syndrome features such as dyslipidemia and hyperinsulinemia. 14, 18, 19 Epidemiologic studies found together with the increase in pediatric obesity, an increased prevalence of nonalcoholic fatty liver disease (NAFLD). 20 NAFLD currently is considered the most frequent chronic liver disease worldwide. 20 
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susceptibility and inappropriate lifestyle (ie, over-/malnutrition and physical inactivity) are the main risk factors for NAFLD both in children and adults. 22, 23 However, the pathogenesis is multifactorial; a growing body of evidence has demonstrated that, among different pathogenic factors, adipocytokines may play pivotal roles in the development and/or progression of NAFLD. 24 Among the adipocytokines involved in NAFLD pathogenesis are those mainly involved in energy balance control, lipid and glucose metabolism, insulin sensitivity, blood pressure, and angiogenesis (adiponectin, leptin, and resistin) as well as those that trigger inflammation (proinflammatory cytokines, including interleukin-6 [IL-6] and tumor necrosis factor-a [TNF-a]). 24 Therefore, in this study, we assessed the prevalence of overweight/obesity in a cohort of Italian children with DS and the possible correlation with NAFLD diagnosed by an ultrasound scan of the liver.
Methods
Children with DS (n = 280; age range 5-18 years) participated in this study. The children were recruited from the DS outpatient clinic of the Bambino Gesù Children's Hospital in Rome from December 2014 until March 2016. Inclusion criteria were diagnosis of DS proven by chromosome analysis; age between 5 and 18 years; and body mass index (BMI) ≥ third percentile for age and sex.
For all children, we collected the clinical history with particular focus on lifestyles (diet and exercise) and the presence of comorbidities. Anthropometric variables (weight, height, BMI) also were measured and collected.
A subpopulation of 84 subjects of the 280 initially enrolled was selected because they had no endocrinologic disorders, hemodynamically significant congenital heart diseases, celiac disease, neoplastic conditions, history of intestinal anomalies requiring bowel resection, and/or ongoing medical intervention and concurrent infections. Second, these subjects underwent further investigations that included anthropometrics (weight, waist circumference [WC], and BMI); ultrasound scan of the liver; and biochemical variables and adipocytokines. The patients also were checked simultaneously for hepatic viral infections (hepatitis A, B, C, D, and E viruses; cytomegalovirus; and Epstein-Barr virus), alcohol consumption, history of parenteral nutrition, and use of drugs known to induce steatosis (eg, valproate, amiodarone, or glucocorticoids) or to affect body weight and carbohydrate metabolism, autoimmune liver disease, metabolic liver disease, Wilson disease, and 1-alpha-antitrypsinassociated liver disease.
Written informed consent was obtained from parents. The study was approved by the Ethics Committee of the Bambino Gesù Children's Hospital and was conducted according to the principles of the Declaration of Helsinki.
Weight was measured without clothing and/or diapers on an electronic digital scale. Standing height was measured via a wall-mounted stadiometer. BMI, defined as weight in kilograms divided by height in meters squared, was calculated. Because BMI varies with age and differs by sex, BMI percentile was calculated with standard growth charts of the World Health Organization, according to the American Academy of Pediatrics Statement for children with DS. 25 WC was measured, with the patient in a standing position, on the horizontal plan between the lowest portion of the rib cage and the iliac crest. Weight, height, and WC were measured by one physician only.
Blood sampling was performed at the time of NAFLD diagnosis after an overnight fast. Laboratory tests by automated commercial methods included analysis of alanine aminotransferase, aspartate aminotransferase (AST), and gamma-glutamyltransferase; total cholesterol; high-density lipoprotein (HDL)-cholesterol; low-density lipoprotein (LDL)-cholesterol; triglycerides; glucose; insulin; and uric acid.
The homeostasis model assessment-insulin resistance (HOMA-IR) was calculated to assess insulin sensitivity and betacell function. 26 HOMA-IR formula was fasting plasma insulin in mU/L × fasting plasma glucose in mmol/L/22.5.
An ultrasound scan of the liver was performed by an experienced radiologist, using an Acuson Sequoia C512 scanner equipped with a 15L8 transducer (Universal Diagnostic Solutions, Oceanside, California). Normal liver/absent steatosis was defined as having normal liver echo-texture; mild steatosis as slight and diffuse increase in fine parenchymal echoes with normal visualization of diaphragm and portal vein borders; moderate steatosis as moderate and diffuse increase in fine echoes with slightly impaired visualization of diaphragm and portal vein borders; and severe steatosis as fine echoes with poor or no visualization of diaphragm, portal vein borders, and posterior portion of the right lobe. 27 The circulating levels of adiponectin, leptin, TNF-a, and IL-6 were measured according to the manufacturer's recommendations by commercially available enzyme-linked immunoassay kits (BioVendor, Heidelberg, Germany).
Statistical Analyses
Statistical analysis was performed with the software packages GraphPad Prism 5.00 and GraphPad Instat 3.05 (GraphPad Software, Inc, San Diego, California). Data are shown as mean ± SD. Two-tailed P values <.05 were considered statistically significant. Multiple comparisons were made with the Spearman correlation. Linear regression analysis was used to study the relationship between the liver fat content and the other variables.
Results
The study population, consisting of 280 children with DS (age range 5-18 years), was screened for overweight/obesity. As reported in Figure 1 (available at www.jpeds.com), we found 191 children with a normal weight (BMI 3-84th percentile), 55 overweight children (BMI 85-94th percentile), and 34 obese children (BMI ≥95th percentile). Therefore, our data showed, in Italian children with DS, a prevalence of 19.64% for overweight and of 12.14% for obesity.
As reported in variables. This subpopulation was subdivided into 2 subgroups based on BMI values: 40 nonobese children with DS (BMI <85th percentile) and 44 overweight/obese children with DS (BMI ≥85th percentile).
As shown in Table I , weight, BMI, WC, total cholesterol, LDLcholesterol, triglycerides, glucose, insulin, and HOMA-IR were found to be greater in obese children with DS compared with nonobese children. Moreover, a significant reduction of AST and HDL-cholesterol was observed in obese children with DS compared with nonobese children. The other biochemical variables were unchanged.
To evaluate the prevalence of NAFLD in the same selected subpopulation of children with DS, we simultaneously performed ultrasound scans of the liver and clinical and laboratory analyses to rule out other causes of fatty liver than NAFLD (Figure 2) .
As reported in Figure 3 , A, the number of children with DS with NAFLD of whatever grade, independently from BMI, was 54 vs 30 without liver disease. These data indicate that the prevalence of children with DS with NAFLD in our study population was 64.3%.
Patients' stratification on the basis of BMI (Figure 3, B) showed that the prevalence of NAFLD was 45% in nonobese children with DS (BMI <85th percentile), whereas the prevalence of NAFLD in obese children with DS (BMI ≥85th percentile) was 82%. Next, as shown in Figure 3 , C-F, patients were stratified for examined metabolic syndrome variables according to the International Diabetes Federation. 28 Stratification of children with DS, based on steatosis severity, demonstrated that the rate of subjects without steatosis was greater in the nonobese group (Figure 4, A) , whereas the most severe forms of steatosis were found in the obese group (Figure 4, B) .
Because several studies demonstrated increased circulating levels of adipocytokines in individuals with DS, in our study we measured IL-6, TNF-a, leptin, and adiponectin and compared their values in the 2 subgroups. 29, 30 As shown in Table II , circulating levels of leptin and TNF-a significantly increased in the 44 overweight/obese children with DS (BMI ≥ 85th percentile) compared with the 40 nonobese subjects. Moreover, our data showed a significant increase of adiponectin levels in nonobese subjects, whereas the levels of IL-6 were similar in the 2 groups.
To evaluate the variables that significantly associated to the presence of steatosis in the studied subpopulation, we performed a Spearman correlation. Our analysis demonstrated that several variables showed a positive correlation with steatosis. In particular, the values of correlation coefficient were 0.37 (P = .0003) for BMI; 0.37 (P = .0004) for WC; 0.25 (P = .001) for triglycerides; 0.22 (P = .003) for LDL-cholesterol; 0.35 (P = .0009) for leptin; and -0.23 (P = .003) for adiponectin.
Furthermore, we assessed the pediatric NAFLD fibrosis index (PNFI), a simple and noninvasive index based on age, WC, and triglycerides, for the prediction of liver fibrosis in children with NAFLD. A PNFI value ≥9 could be used to rule in liver fibrosis without performing liver biopsy. 31 Our data showed that PNFI positively correlated with steatosis (0.26, P = .001) in all the subpopulation of children with DS, but its value was ≥9 in overweight/obese children with DS only (Figure 5 ; available at www.jpeds.com).
Discussion
We report the prevalence of NAFLD and its association with obesity-related features in Italian children with DS. Several studies showed an increased prevalence of overweight and obesity in adults and children with DS. 7, 32 Basil et al 16 analyzed 303 patients with DS, aged between 2 and 18 years, and reported that the prevalence of obesity was 47.8%. A previous study, in which the investigators compared 1596 Dutch children with DS with general pediatric population, showed that overweight and obesity were more frequent in subjects with DS. In particular, the rate of overweight was 25.5% in boys and 32.0% in girls, and obesity rate was 4.2% in boys and 5.1% in girls. 12 A recent literature review 7 reported that the combined prevalence of overweight and obesity varied between studies from 23% to 70%. We found that in Italian children with DS the tendency to be overweight/obese was approximately 31.8%. However, the prevalence rate is not different from the data reported by "OKkio alla salute 2014," a national surveillance initiative program for overweight/obesity in the Italian pediatric population. 33 The greater tendency to overweight/obesity in individuals with DS is likely caused by a lower resting metabolic rate, less physical activity, a greater consumption of energy-rich and nutrient-poor food, and the increased risk of hypothyroidism and diabetes. [34] [35] [36] We hypothesized that the similarity in the overweight/obesity rate between our study population and the general pediatric population could be explained by the fact that our center may be considered as a specialty clinic that aims to identify and address many healthcare needs of children and adolescents with DS. 37 In fact, our patients with DS undergo periodic follow-up, during which anthropometric variables are monitored. In this way, children with DS, who have a tendency to gain weight, are followed on an early basis by nutritionist with a strict weight monitoring. Therefore, it is conceivable that our study population may not represent the actual situation of Italian children with DS. The trend of obesity in children with DS could be same as observed in the general population because the family perception of the child's weight status and efforts to promote healthy lifestyle play a key role in long-term weight control. 38 It is well known that obesity in the pediatric population frequently is associated with other diseases, including type 2 diabetes, dyslipidemia, hyperinsulinemia, hypertension, and obstructive sleep apnea, with a consequent increased cardiovascular risk. 39 As expected, these comorbidities also are frequent in overweight/obese children with DS. 14, 18, 19 Congenital heart diseases are the main causes of death among young with DS (<20 years old). 40 However, children and adults with DS also experienced excess mortality as the result of other causes, such as cancers, infections, type 2 diabetes, and liver cirrhosis. 41 Fortunately, we are seeing a marked decline of mortality rate in individuals with DS due to improvement of surgical and early therapeutic intervention in DS morbidities. 42 The increase of life expectancy may run in parallel with the increased risk of chronic noncommunicable disease, such as type 2 diabetes, cardiovascular disease, metabolic syndrome, and NAFLD, as observed in the general population. 43 Thus, the screening for NAFLD could be medically necessary to improve the quality of life of these patients.
It is widely accepted that NAFLD has to be considered as an additional feature of metabolic syndrome in both adults and children. 44, 45 Our study showed that the prevalence of NAFLD in both normal-weight children with DS (45%) and those who are overweight/obese (82%) is greater if compared with the European pediatric nonobese population (5.7%) or obese population (33%). 20 Moreover, we found at least one component of metabolic syndrome associated with children with DS who have NAFLD that exhibited a greater percentage of these variables respect to subject without NFLD.
We excluded DS-related congenital and extrahepatic diseases that could induce the development of NAFLD; thus, the high prevalence of NAFLD in children with DS, independently from BMI, could depend on other pathogenic factors such as the imbalance of production/release of adipocytokines. The most important adipocytokines influencing NAFLD development and its progression to nonalcoholic steatohepatitis are leptin, adiponectin, IL-6, and TNF-a. 24 Several studies demonstrated increased circulating levels of adipocytokines in individuals with DS. 29, 30 We found that leptin and TNF-a were increased in overweight/obese children with DS compared with nonobese subjects who displayed augmented levels of adiponectin. The trend of leptin and adiponectin levels correlated with steatosis, as well as BMI, WC, triglycerides, and LDL-cholesterol. These findings could not explain the high prevalence of NAFLD in normal-weight children with DS. However, we found that nonobese children with DS exhibited a mean value of TNF-a levels greater than those reported in the general population by other authors 46 and showed an inexplicable elevation of AST levels, thus suggesting that children with DS may have an increased risk of systemic inflammation of unknown origin that could explain their susceptibility to NAFLD.
Finally, our data showed that in children with DS steatosis is correlated positively with PNFI, but this test is predictive of fibrosis (≥9) in obese children with DS only. Elevated AST levels found in nonobese children with DS have been reported to reflect a progressive and more serious condition. 47 The fact that we assessed NAFLD by ultrasound scan could represent a limitation of our study, because this does not allow us to define all the histologic patterns of the disease. 48 However, as suggested by Vajro et al, 47 NAFLD is a diagnosis of exclusion, in which ultrasound scans and liver function tests should be performed as a first step, but in the case of a bright liver, other causes of steatosis liver should be investigated based on the patient's age and clinical features.
In summary, we demonstrated that, independently from the obese phenotype, children with DS display a greater risk to develop NAFLD than the general pediatric population. These data suggest that, together with a management program comprising all strategies (diet and physical activity) to maintain a healthy weight, 25 the inclusion of a careful monitoring of biochemical and imaging variables could allow the early detection of obesity-related comorbidities, such as NAFLD. 
